Targeting Genetic Diseases at Their Source


At BridgeBio, we have one reason to exist: to create new and better medicines for patients with genetically driven diseases. We want to help as many patients as possible, as fast as possible.

To do this, we had to think about drug development in a whole new way — from how we identify potentially transformational new medicines to how we finance our company.

We Do This By:


Finding the right starting points to target diseases at their source.

Using a combination of a systematic assessment of the genetic disease landscape and informed diligence on the latest research, we find indications with clear mechanisms of pathogenesis that are ripe for translation into disease-modifying drugs.


Building products with world-class R&D personnel.

We employ over 50 scientists and work closely with leading academics to prosecute a wide variety of drug programs at the highest level of scientific rigor. We combine biopharmaceutical veterans with up-and-coming leaders to drive entrepreneurial thinking grounded by experience.


Employing a lean, capital efficient model.

We house each effort in an individual subsidiary company supported by shared central resources. This efficient, de-centralized corporate structure enables focus at level of each disease, but provides diversification and the ability to scale across many opportunities.

Our Core Values Are:

Put Patients First


Be Radically Transparent

Think Independently

Do Everything as Fast as Possible

© 2019 BridgeBio Inc.